Conditionally reprogrammed cells as a novel tool for biobanking

条件重编程细胞作为生物样本库的新工具

• 批准号: 8547303
• 负责人: Richard Schlegel
• 金额: $ 40.05万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2016-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8547303
• 关键词: Address; Algorithms; Attention; Biological; Biopsy; Blood specimen; Cancer Biology; Cancer Patient; Categories; Cell Culture System; Cell Culture Techniques; Cells; Conditioned Culture Media; Cultured Tumor Cells; Diagnostic; Drug Targeting; Evaluation; FarGo; Foundations; Freezing; Future; Generations; Genetic Materials; Genotype; Harvest; Human; Immunohistochemistry; Investigation; Journals; Laboratories; Medical center; Medicine; Methods; Molecular; Molecular Analysis; Monitor; Mutation; Mutation Spectra; Neoplasm Circulating Cells; New England; Normal Cell; Normal tissue morphology; Oncologist; Operative Surgical Procedures; Pathology; Patients; Pharmaceutical Preparations; Pharmacotherapy; Phenotype; Preparation; Primary Neoplasm; Process; Proteomics; Publishing; RNA; Research; Resource Sharing; Sample Size; Sampling; Signal Pathway; Specimen; System; Technology; Temperature; Therapeutic; Time; Tissues; Tumor Tissue; Vaccines; Validation; biobank; exome sequencing; human tissue; neoplastic cell; novel; novel strategies; public health relevance; repository; research study; response; therapeutic evaluation; tool; tumor

DESCRIPTION (provided by applicant): Our recent discovery of conditional reprogramming (CR) to generate cell cultures from human tissues offers new and exciting opportunities for biospecimen repositories. This cell technology makes it possible to rapidly generate cell cultures from surgical specimens and small biopsies, thereby providing an unlimited amount of patient material for genetic and proteomic analysis. However, this technology goes further: it will allow the functional analysis of tumor cells and comparison with the patients' normal cells from the same tissue. In this proposal we will extend and validate aspects of the CR technology and optimize its usage for biobanking. It is important to verify that the genotype and functional responses of CR cells mimics that of the primary tumor and experiments will address these issues using exome sequencing and TruSeq analysis. We will also examine whether the CR cells can predict patient responses to therapies, as we have recently described for a single case in the New England Journal of Medicine. Indeed, we believe that this technology will alter how Pathology departments and tissue repositories freeze patient specimens. Rather than simply quick freezing samples for future molecular analysis, tumor samples will be frozen in cryopreservative, which will additionally permit the generation of cell cultures for diagnostic and therapeutic evaluation.

描述（由申请人提供）：我们最近发现条件重编程（CR）可从人体组织生成细胞培养物，为生物样本库提供了令人兴奋的新机会。这种细胞技术使得从手术标本和小活组织检查中快速产生细胞培养物成为可能，从而为遗传和蛋白质组分析提供无限量的患者材料。然而，这项技术更进一步：它将允许对肿瘤细胞进行功能分析，并与来自同一组织的患者正常细胞进行比较。在本提案中，我们将扩展和验证 CR 技术的各个方面，并优化其在生物样本库中的使用。重要的是要验证 CR 细胞的基因型和功能反应是否模仿原发肿瘤的基因型和功能反应，并且实验将使用外显子组测序和 TruSeq 分析来解决这些问题。我们还将检查 CR 细胞是否可以预测患者对治疗的反应，正如我们最近在《新英格兰医学杂志》上对单个病例所描述的那样。事实上，我们相信这项技术将改变病理科和组织储存库冷冻患者标本的方式。肿瘤样本将被冷冻在冷冻保存剂中，而不是简单地快速冷冻样本以供将来的分子分析，这将另外允许生成用于诊断和分析的细胞培养物。 治疗评价。